Soluble tumor necrosis factor-like weak inducer of apoptosis plasma levels as a novel biomarker of endothelial function in prevalent orthotopic heart transplant recipients

Transplantation Proceedings

Volumn 43, Issue 5, 2011, Pages 1900-1903

  Przybylowski, P ^a   Malyszko, J S ^b   Malyszko, J ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AZATHIOPRINE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; CYCLOSPORIN; EVEROLIMUS; GLUCOSE; HIGH SENSITIVITY C REACTIVE PROTEIN; LIPID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; UREA;

APOPTOSIS; ARTICLE; BLOOD CELL COUNT; CARDIAC GRAFT REJECTION; CHOLESTEROL BLOOD LEVEL; CONGESTIVE CARDIOMYOPATHY; CREATININE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; ISCHEMIC CARDIOMYOPATHY; KIDNEY FUNCTION; LEUKOCYTE COUNT; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; ORTHOTOPIC TRANSPLANTATION; PREVALENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL;

ADULT; APOPTOSIS; BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; HEART TRANSPLANTATION; HUMANS; MIDDLE AGED; TUMOR NECROSIS FACTORS;

EID: 79959427383     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.03.040     Document Type: Article

References (24)

1. B.W. Miller Chronic kidney disease in solid-organ transplantation Adv Chronic Kidney Dis 13 2006 29
2. A. Chandrakantan, A.M. de Mattos, and D. Naftel Increasing referral for renal transplant evaluation in recipients of nonrenal solid-organ transplants: a single-center experience Clin J am Soc Nephrol 1 2006 832
3. R.D. Blom, and P.P. Reese Chronic kidney disease after nonrenal solid-organ transplantation J Am Soc Nephrol 18 2007 3031
4. A.O. Ojo, P.J. Held, and F.K. Port Chronic renal failure after transplantation of a nonrenal rogan N Engl J Med 349 2003 931
5. National Kidney Foundation K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2002 S1
6. W.M. McClellan, W.D. Flanders, and R.D. Langston Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study J Am Soc Nephrol 13 2002 1928
7. I.M. Hamour, F. Omar, and H.S. Lyster Chronic kidney disease after heart transplantation Nephrol Dial Transplant 24 2009 1655
8. J. Malyszko, P. Przybylowski, and J.S. Malyszko Prevalence of chronic kidney disease in orthotopic heart transplant recipients and kidney allograft recipients using the new Chronic Kidney Disease Epidemiology Collaboration formula Transplant Proc 42 2010 4251
9. K. Klausen, K. Borch-Johnsen, and B. Feldt-Rasmussen Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes Circulation 110 2004 32
10. J. Malyszko Endothelial dysfunction in chronic kidney disease Clin Chim Acta 411 2010 1412
11. T. Bombeli, M. Mueller, and A. Haeberli Anticoagulant properties of the vascular endothelium Thromb Haemost 77 1997 408
12. J.A. Winkles The TWEAK-Fn14 cytokine-receptor axis: Discovery, biology and therapeutic targeting Nat Rev Drug Discov 7 2008 411
13. M. Girgenrath, S. Weng, and C.A. Kosteck TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration EMBO J 25 2006 5826
14. S. Campbell, L.C. Burkly, and H.X. Gao Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells J Immunol 176 2006 1889
15. Y. Chicheportiche, P.R. Bourdon, and H. Xu TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis J Biol Chem 272 1997 32401
16. M.I. Yilmaz, J.J. Carrero, and A. Ortiz Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease Clin J Am Soc Nephrol 4 2009 1716
17. Modification of diet in Renal Disease Study Group Creatinine filtration, secretion and excretion during progressive renal disease Kidney Int 36 1989 S73
18. E. Chorianopoulos, M. Rosenberg, and C. Zugck Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure Eur J Heart Fail 11 2009 1050
19. M. Jain, A. Jakubowski, and L. Cui A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure Circulation 119 2009 2058
20. E. Chorianopoulos, K. Jarr, and H. Steen Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome Atherosclerosos 211 2010 322
21. S. Kralisch, M. Ziegelmeier, and A. Bachmann Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease Atherosclerosis 199 2008 440
22. M.I. Yilmaz, J.J. Carrero, and J.L. Martín-Ventura Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation Clin J Am Sc Nephrol 5 2010 1174
23. J.J. Carrero, A. Ortiz, and A.R. Qureshi Additive effects of soluble TWEAK and inflammation on mortality in hemodilaysis patients Clin J Am Soc Nephrol 4 2009 110
24. M.I. Yilmaz, A. Sonmez, and A. Ortiz Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes Clin J Am Soc Nephrol 6 2011 785